Idiopathic systemic capillary leak syndrome: a case report.

Background

Idiopathic systemic capillary leak syndrome (ISCLS) is a rare and fatal disease, first described by Clarkson in 1960. The first case of ISCLS was reported in a 32-year-old woman who experienced periodic sudden and unexplained movement of plasma from intravascular compartment to interstitial space due to increased capillary permeability [ 1 ]. ISCLS is characterized by recurrent episodes of edema, hypovolemic shock, hypoalbuminemia, and hemoconcentration. Monoclonal gammopathy is common among patients with SCLS, which guides the diagnosis but is not considered a major diagnostic criterion [ 2 ]. Other possible differential diagnoses include polycythemia vera, sepsis, anaphylaxis, and reactions to certain drugs and toxins [ 2 , 3 ].

Since ISCLS is rarely encountered in clinical practice and shows a variety of manifestations, it is difficult to differentiate from other disorders, which might cause a delay in diagnosis and development of life-threatening complications. In patients with ISCLS, acute kidney injury (AKI) is a common complication that sometimes culminates to chronic renal failure requiring hemodialysis [ 3 – 7 ]. Herein, we report a case of ISCLS with recurrent AKI that was successfully controlled with theophylline and long-acting oral β2-agonist administration.

Case presentation

Clinical history and initial laboratory data

A 47-year-old man was admitted to our hospital after presenting to the emergency department in March 2017, with complaints of general weakness, lower back pain and abdominal pain that started on the same day. The patient had no underlying diseases or history of taking any medications. He was a never-smoker, and social drinker. There were no significant recent changes in his lifestyle or diet, except overworking.

The patient was alert and only a dry tongue and axilla were observed during physical examination. His vital signs were stable at presentation, but the blood pressure decreased to 74/60 mmHg, 3 h after arrival in the emergency room. Initial laboratory tests revealed several abnormalities (Table 1 ), including an elevated white blood cell count (WBC) of 29,180 × 10 6 cells/L, hemoglobin (Hgb) of 22.6 g/dL, hematocrit (Hct) of 66.1%, blood urea nitrogen (BUN) of 28 mg/dL, creatinine (Cr) of 1.95 mg/dL, fractional excretion of sodium (FENa) of 0.13%, hypoalbuminemia with serum albumin level of 2.6 g/dL, C-reactive protein (CRP) level of 7.7 mg/L, and procalcitonin level of 0.8 ng/ml. Cardiac markers were normal (creatine kinase-MB = 0.94 ng/ml, troponin-I < 0.006 ng/ml). Arterial blood gas analysis (ABGA) showed normal anion gap metabolic acidosis with respiratory compensation (pH = 7.352, PaCO 2 = 24.5 mmHg, PaO 2 = 117 mmHg, HCO 3 = 13.3 mmHg, and lactic acid = 3.0 mmol/L). Non-enhanced abdominal and pelvic computed tomography (CT) scans showed normal sized kidney and borderline splenomegaly. Doppler echocardiography showed normal global left ventricular (LV) systolic function, concentric LV hypertrophy, and minimal amount of pericardial effusion. Owing to the elicitation of polycythemia on blood examination, bone marrow biopsy was performed based on the suspicion of a reactive marrow, which revealed no abnormalities or JAK2 gene V617F mutation. Serum protein electrophoresis returned normal results and antinuclear antibody was negative. Table 1 Laboratory data on admission Parameter Unit 1st admission 2nd admission Reference range White blood cell [WBC] 10 9 /L 29.2 30.2 3.0—9.0 Hemoglobin [Hgb] g/dL 22.6 19.7 13—17 Hematocrit [Hct] % 66.1 59.3 40—50 blood urea nitrogen [BUN] mg/dL 28 39 8—9 Creatinine [Cr] mg/dL 1.95 2.93 0.67—1.17 Sodium [Na] mEq/L 134 126 135—146 Potassium [K] mEq/L 4.8 6.6 3.5—5.3 Albumin [Alb] g/dL 2.6 3.6 3.3—4.9 C-reactive protein [CRP] mg/L 7.7 1.1 0—5.0 procalcitonin ng/mL 0.8 N/C 0—0.5 CK-MB ng/mL 0.94 0.91 0—5 Troponin-I ng/mL < 0.006 < 0.006 0—0.78 JAK2 gene V617F mutation Negative - ANA-titer Negative - serum protein electrophoresis Normal - serum Free light chain—Kappa mg/L 32.3 3.3—19.40 serum Free light chain—Lambda mg/L 15.7 5.71—26.30 serum Free light chain—K/L ratio 2.057 - IgG mg/dL 1,224 - - IgG1 mg/dL 909 - - IgG2 mg/dL 206 - - IgG3 mg/dL 36.5 - - IgG4 mg/dL 0.4 - IgA mg/dL 150 - IgM mg/dL 64 -

Clinical course

Features of dehydration coupled with the laboratory findings suggested pre-renal AKI and hypovolemic shock caused by decreased effective circulating volume. Despite administration of massive volume resuscitation and diuretics, severe hyperkalemia (serum potassium = 7.8 mEq/L), anuria and recurrent hypotension ensued. Ceftriaxone was started as an empirical antibiotic as the cause of shock was uncertain and WBC count as well as CRP levels were elevated. On the second day of hospitalization, the patient complained of pain, redness and swelling in the left lower leg. Thereafter, an ultrasonography was performed, which ruled out deep vein thrombosis; however, subcutaneous edema was evident. As these findings suggested cellulitis, ceftriaxone was switched to cefazolin. The patient recovered dramatically on the third day of hospitalization and was discharged on the tenth day with WBC count of 9,080 × 10 6 cells/L, Hgb of 13.4 g/dL, BUN/Cr of 9/0.81 mg/dL and albumin of 4.2 g/dL. He remained symptomless for 3 months after discharge.

Three months after the last admission, the patient visited our hospital again because of sudden dizziness and dyspnea. On admission, the blood pressure was 86/50 mmHg, pulse rate was 104/min, respiratory rate was 20/min, and his body temperature was 36.8℃. The laboratory results showed an increased WBC of 30,150 × 10 6 cells/L, Hgb of 19.7 g/dL, Hct of 59.3%, BUN/Cr of 39/2.93 mg/dL and decreased albumin level of 3.6 g/dL. The levels of CRP (1.1 mg/L) and cardiac markers (creatine kinase-MB = 0.91 ng/ml, Troponin-I < 0.006 ng/ml) were within normal limits. The FENa was 0.1% suggesting pre-renal AKI. The ABGA showed normal anion gap metabolic acidosis with respiratory compensation (pH = 7.34, PaCO 2 = 24.6 mmHg, PaO 2 = 142 mmHg, HCO 3 = 12.9 mmHg, and lactic acid = 2.4 mmol/L). Kappa and lambda free light chains were 32.3 and 15.7 mg/dL, respectively, and the Kappa/lambda ratio was 2.057. Total serum IgG was 1224 mg/dL, and subclass distribution was a s follows: IgG1 of 909.0, IgG2 of 206.0, IgG3 of 36.5, and IgG4 of 0.4 mg/dL. Serum protein electrophoresis results was normal and non-enhanced chest CT showed no abnormalities.

A clinical diagnosis of ISCLS was made on the basis of recurring clinical presentation of hypotension, hemoconcentration, and hypoalbuminemia, after excluding other reasons of shock, such as septic, cardiogenic, bleeding and toxin. His symptoms improved greatly after oxygen supplementation and massive volume replacement with normal saline. The hemoconcentration and AKI also resolved within the next few days (Fig. 1 , a-d). Based on the previous studies, bambuterol 10 mg (long-acting oral β2-agonist) and theophylline 400 mg once-a-day were prescribed on day 3 of hospitalization [ 4 , 5 ]. He was discharged from the hospital on day 5 post-admission, after being instructed to continue the same doses of oral bambuterol and theophylline. After 4 months of discharge, he experienced headache and flank discomfort suggesting a prodrome of acute attack of ISCLS. However, laboratory investigations, did not reveal significant abnormalities. The bambuterol dose was increased from 10 to 15 mg and the patient has been followed for 5 years without any symptoms or recurrence of ISCLS. As COVID-19 vaccination is not recommended for SCLC patients, he was followed by strict precaution without vaccination. He experienced COVID-19 infection in June 2022, but recovered well without SCLS episode while continuing the same medication he had been maintaining. The patient’s Hgb, albumin, Cr, and estimated glomerular filtration rate (eGFR) values during the follow up are shown in the Fig. 2 a-d. Fig. 1 a Hemoglobin, b albumin, c creatinine, and d eGFR values during first and second attacks Fig. 2 a Hemoglobin, b albumin, c creatinine, and d eGFR values during follow up

Discussion and conclusion

ISCLS is a very rare disorder characterized by recurrent episodes of shock, hypoalbuminemia, and hemoconcentration. It is caused by a dysfunction of the vascular endothelium that leads to shift of fluid and proteins from the intravascular space to the interstitial space [ 1 – 3 , 8 ].

The patient in the present case experienced two similar fatal attacks of hypovolemic shock, AKI, hypoalbuminemia, and hemoconcentration within a short duration of 4 months. The initial laboratory results showed normal serum protein electrophoresis and there was no other evidence of hematologic disorder on bone marrow biopsy. Although cellulitis was diagnosed, it was not considered as a precipitant factor of the first attack because it was mild and developed a few days after onset of the attack. Moreover, during the second attack, the final diagnosis of ISCLS was made after excluding all other possible causes of shock.

At present, there is no known curative treatment for ISCLS [ 3 , 4 , 6 , 9 ]. The capillary leak phase with hypovolemia and hypotension is managed by vigorous fluid resuscitation, while in the recovery phase, diuretics are used to improve generalized edema and oliguria, and hemodialysis may be considered in severe cases [ 10 ]. In addition to conservative treatment, some prophylactic treatments have also been attempted. The pathophysiology of ISCLS is uncertain but it has been shown that macromolecular leakage in response to various stimuli, including histamine and bradykinin, can be inhibited by pretreatment with beta-2 stimulants like terbutaline-selective beta-2 stimulant and isoprenaline [ 4 ]. Combination of terbutaline and theophylline have shown good prognosis in some case series [ 4 , 5 , 8 ]. In addition, several studies have demonstrated better efficacy of intravenous immunoglobulin therapy (IVIG) than β2-agonists. Thus, IVIG has emerged as the most commonly used first-line prophylactic therapy in ISCLS and is effective at a dose of 2 g/kg once a month. [ 5 , 6 , 9 ]. However, in the present case, we could not prescribe IVIG due to high cost of treatment (29 USD for 1 g) and limitation of medical reimbursement system in Korea. The patient in this case reported no recurrence after initiating combination treatment with theophylline and bambuterol. However, if the patient experiences another attack in the future, IVIG infusion should be considered.

Previous case reports have described a range of complications associated with ICSLS [ 2 , 7 , 11 ]. One such report documenting a case of severe chronic ISCLS requiring daily hemodialysis, stated AKI as one of the most common manifestations of capillary leak syndrome [ 7 ]. Another study suggested intravascular volume depletion and cytokine-induced injury as contributors of acute tubular necrosis [ 2 ]. In our case, the patient experienced AKI in every attack of ISCLS. Although renal function fully recovered after the first attack, the eGFR remained below 70 ml/min/m 2 after the second attack as shown in Fig. 2 . This suggested that recurrent ISCLS attacks cause gradual deterioration of renal function, eventually resulting in part-permanent impairment.

Several studies have found monoclonal gammopathy of undetermined significance and multiple myeloma to be associated with SCLS [ 8 ]. In the present case, M-protein was not detected in the serum, but kappa/lambda was too high to be attributed to AKI alone. The patient received regular monitoring for multiple myeloma based on the recommendation of a previous case report that showed progression to multiple myeloma after diagnosis of the systemic capillary leak syndrome [ 6 , 9 ]. In our case, serum kappa/lambda ratio had normalized over time and remained within normal range as shown in Fig. 3 . Fig. 3 The trend of Kappa/Lambda ratio

In the present case, the patient complained of abdominal and lower back pain, but pain focus was unclear on the initial abdominal and pelvic CT examination (Fig. 4 a). The only notable feature was thickening of abdominal wall and muscles, especially psoas major and erector spinae. However, the pain resolved spontaneously within a few days and follow-up CT after 4 days showed intermittent improvement in muscle edema (Fig. 4 b). These findings suggested that muscle edema by capillary leak could trigger pain and even develop into compartment syndrome Also, compartment syndrome by capillary leak has been described in a few case reports in the past [ 11 – 14 ]. Fig. 4 a Abdomen and pelvis CT demonstrates generalized edema of abdominal wall muscles. b Decreased muscle edema on subsequent chest CT 4 days later

During the COVID-19 pandemic, a few cases were reported where patients experienced an episode of systemic capillary leak syndrome following COVID-19 vaccination or infection, especially those with a history of SCLS [ 15 , 16 ]. According to European Medicines Agency, COVID-19 vaccination with adenoviral vectors is not recommended for patients with a history of SCLS. Since COVID-19 vaccination or infection can act as triggers for SCLS recurrence [ 17 ], he was followed by strict precaution without vaccination. He contracted COVID-19 infection in June 2022, but recovered well without SCLS episode while continuing the same medication he was maintaining. The relatively simple, inexpensive, and easy-to-adapt maintenance treatment he took once a day effectively prevented the recurrence of ISCLS episodes in usual times, and also effectively prevented the occurrence of SCLS episodes even when the risk was increased due to acute viral infection.

In conclusion, we reported a case of a patient with ISCLS who experienced two severe episodes of the disease, and has been followed for 5 years without recurrence even in the situation of COVID-19 infection, after being prescribed bambuterol and theophylline. ISCLS is a very rare pathology to come across for a clinician and it takes a long time to be diagnosed because other possible causes need to be excluded before reaching a diagnosis. Early diagnosis, treatment and prophylaxis through accumulated clinical data can prevent ISCLS from recurring as well as the development of various associated complications. Therefore, clinicians should be aware of the different clinical characteristics and treatment options of ISCLS.

Abbreviations

Idiopathic systemic capillary leak syndrome

Left ventricular

White blood cell

Hemoglobin

Hematocrit

Blood urea nitrogen

Creatinine

Fractional excretion of sodium

C-reactive protein

Arterial blood gas analysis

Computed tomography

Immunoglobulin G

Acute kidney injury

Intravenous immunoglobulin therapy

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements

Not applicable.

Authors’ contributions

HYL, JS and JHH were involved in diagnosis, management and follow-up of the patient at all stages. SHK and JS contributed substantially and significantly to the literature review, drafting of the initial manuscript, critical revision and preparation of the final version. All authors have participated sufficiently in the work to take public responsibility for the presented content. All the authors have contributed, read and approved the final and revised version of the manuscript.

Funding

This research was supported by the Chung-Ang University Research Grants in 2020. This funding source had no role in the report of this case and did not have any role during its interpretation, or decision to submit report.

Records and data pertaining to this case are in the patient’s secure medical records in the Chung-Ang University Hospital. If needed, the relevant material can be provided by corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Consent for publication

Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient.

Competing interests

The authors declare that they have no competing interests.

References

1. Clarkson B Thompson D Horwith M Luckey EH Cyclical edema and shock due to increased capillary permeability Am J Med 1960 29 193 216 10.1016/0002-9343(60)90018-8 13693909

2. Kapoor P Greipp PT Schaefer EW Mandrekar SJ Kamal AH Gonzalez-Paz NC Kumar S Greipp PR Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience Mayo Clin Proc 2010 85 10 905 912 10.4065/mcp.2010.0159 20634497 PMC2947962

3. Siddall E Khatri M Radhakrishnan J Capillary leak syndrome: etiologies, pathophysiology, and management Kidney Int 2017 92 1 37 46 10.1016/j.kint.2016.11.029 28318633

4. Tahirkheli NK Greipp PR Treatment of the systemic capillary leak syndrome with terbutaline and theophylline A case series Ann Intern Med 1999 130 11 905 909 10.7326/0003-4819-130-11-199906010-00015 10375339

5. Dowden AM Rullo OJ Aziz N Fasano MB Chatila T Ballas ZK Idiopathic systemic capillary leak syndrome: novel therapy for acute attacks J Allergy Clin Immunol 2009 124 5 1111 1113 10.1016/j.jaci.2009.06.043 19703708

6. Xie Z Chan EC Long LM Nelson C Druey KM High-dose intravenous immunoglobulin therapy for systemic capillary leak syndrome (Clarkson disease) Am J Med 2015 128 1 91 95 10.1016/j.amjmed.2014.08.015 25193271 PMC4282822

7. Alkhunaizi AM Kabbani AH ElTigani MA Chronic idiopathic systemic capillary leak syndrome: a case report Allergy Asthma Clin Immunol 2019 15 34 10.1186/s13223-019-0347-0 31160895 PMC6540441

8. Druey KM Greipp PR Narrative review: the systemic capillary leak syndrome Ann Intern Med 2010 153 2 90 98 10.7326/0003-4819-153-2-201007200-00005 20643990 PMC3017349

9. Zipponi M Eugster R Birrenbach T High-dose intravenous immunoglobulins: a promising therapeutic approach for idiopathic systemic capillary leak syndrome BMJ Case Rep 2011 2011 bcr1220103599 10.1136/bcr.12.2010.3599 22696704 PMC3089932

10. de PinetonChambrun M Mathian A Combes A Luyt CE Amoura Z Handling shock in idiopathic systemic capillary leak syndrome (Clarkson's disease): less is more-comment Intern Emerg Med 2020 15 2 347 348 10.1007/s11739-019-02144-x 31273675

11. Lamou H Grassmann JP Betsch M Wild M Hakimi M Windolf J Jungbluth P Systemic capillary leak syndrome associated with a rare abdominal and four-limb compartment syndrome: a case report J Med Case Rep 2014 8 196 10.1186/1752-1947-8-196 24934689 PMC4131808

12. Bichon A Carvelli J Bourenne J Gainnier M Harle JR Schleinitz N Idiopathic systemic capillary leak syndrome: 2 cases with misleading presentation Rev Med Interne 2021 42 9 660 664 10.1016/j.revmed.2021.03.325 33846036

13. Dolberg-Stolik OC Putterman C Rubinow A Rivkind AI Sprung CL Idiopathic capillary leak syndrome complicated by massive rhabdomyolysis Chest 1993 104 1 123 126 10.1378/chest.104.1.123 8325053

14. Davies K Thomas K Barton L Williams C Aujayeb A Premchand N Idiopathic systemic capillary leak syndrome (Clarkson's disease) presenting with recurrent hypovolemic shock Acute Med 2021 20 1 74 77 10.52964/AMJA.0843 33749696

15. Case R Ramaniuk A Martin P Simpson PJ Harden C Ataya A Systemic capillary leak syndrome secondary to coronavirus disease 2019 Chest 2020 158 6 e267 e268 10.1016/j.chest.2020.06.049 32622823 PMC7332444

16. Matheny M Maleque N Channell N Eisch AR Auld SC Banerji A Druey KM Severe exacerbations of systemic capillary leak syndrome after COVID-19 vaccination: a case series Ann Intern Med 2021 174 10 1476 1478 10.7326/L21-0250 34125573 PMC8252024

17. Beber A Dellai F Abdel Jaber M Peterlana D Brunori G Maino A Systemic capillary leak syndrome triggered by sars-cov2 infection: case report and systematic review Scand J Rheumatol 2022 51 1 67 69 10.1080/03009742.2021.1917145 34169783